Pharmaceutical companies lose an estimated $188 billion annually in revenues in the U.S. because patients fail to take their prescribed medications, according to a study by consulting firm Capgemini.
Even for the countries in Western Europe such as the Netherlands where medication is fully covered, adherence is still a major concern and growing issue.
In the U.S. Medicare payment reforms aim to place an emphasis on preventive health measures affecting other sectors in health care, pharmaceutical companies are no longer alone in facing poor medication adherence.
The question is are these false promises or actual achievable objectives because of wrong targeting?
Via Lionel Reichardt / le Pharmageek, Rémy TESTON, Pharmacomptoir / Corinne Thuderoz